Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ROIV - Roivant Sciences Ltd.
Market Cap 9.06B P/E - EPS this Y 371.50% Ern Qtrly Grth -
Income 4.35B Forward P/E -10.83 EPS next Y -131.20% 50D Avg Chg 15.00%
Sales 123.24M PEG - EPS past 5Y - 200D Avg Chg 45.00%
Dividend N/A Price/Book 7.75 EPS next 5Y - 52W High Chg -2.00%
Recommedations 1.70 Quick Ratio 27.50 Shares Outstanding 805.85M 52W Low Chg 311.00%
Insider Own 20.63% ROA -13.77% Shares Float 421.63M Beta 1.34
Inst Own 62.12% ROE 105.80% Shares Shorted/Prior 30.93M/27.69M Price 11.81
Gross Margin - Profit Margin 3,624.14% Avg. Volume 4,793,029 Target Price 15.90
Oper. Margin -774.17% Earnings Date Jun 26 Volume 1,997,846 Change -1.01%
Healthcare | Biotechnology | United Kingdom
About Roivant Sciences Ltd.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences Ltd. News
04/02/24 Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
03/27/24 Stocks to Watch Wednesday: Carnival, Robinhood, Trump Media, Merck
03/26/24 Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
02/14/24 Roivant Sciences Third Quarter 2024 Earnings: Beats Expectations
02/13/24 Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
02/10/24 Roivant Sciences Ltd President & COO Eric Venker Sells 96,950 Shares
01/30/24 Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
12/20/23 Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
12/14/23 Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
11/28/23 Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
11/27/23 Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
11/13/23 Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
11/10/23 Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors
10/30/23 Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
10/23/23 Roche acquires Telavant, rights to bowel disease drug
10/23/23 Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
10/13/23 Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer
10/05/23 Insider Sell: Eric Venker Sells 1,200,000 Shares of Roivant Sciences Ltd (ROIV)
09/30/23 Insider Sell: President & COO Eric Venker Sells 500,000 Shares of Roivant Sciences Ltd (ROIV)
09/26/23 Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
ROIV Chatroom

User Image Nbanderson51 Posted - 4 days ago

$ROIV http://archive.fast-edgar.com/20240412/A9ZZ622MB222Q2Z2222222ZZGWGUZ2682562

User Image PatBull6912 Posted - 5 days ago

$ROIV Roivant will form a new "vant" company to develop and commercialize Pfizer's TL1A inhibitor for ulcerative colitis.

User Image PatBull6912 Posted - 6 days ago

$ROIV Must have cursed it; which is way too easy to do these days.

User Image PatBull6912 Posted - 6 days ago

$ROIV What a strange daily pattern! Looks like we're going ballistic Mav!!!

User Image Winner_Chicken_Dinner Posted - 6 days ago

$ROIV 12+🫣

User Image bs010101 Posted - 1 week ago

$ABUS $ROIV Roivant's April 8th, 2024 presentation: https://investor.roivant.com/static-files/ce876aa0-213a-4563-92f1-013df7b3921a

User Image Jdvm Posted - 1 week ago

$ROIV If it goes down more time to do the buyback.🤑

User Image Buqqets Posted - 1 week ago

$MRNA $ABUS $ROIV

User Image Buqqets Posted - 1 week ago

$MRNA remember when a judge ruled that they are infringing on at least 4 patents and owe billions of dollars? $ABUS $ROIV

User Image LibsRot Posted - 1 week ago

$ROIV Time to buy Arbutus Bio…

User Image brs555 Posted - 1 week ago

$ROIV This stock is such a pig. Limited downside but no real upside for a while.....

User Image Capitulation_0 Posted - 1 week ago

$ROIV This stock loves dip buyers... luring them in like an expert angler.

User Image jeojackson Posted - 1 week ago

$ROIV What the heck?

User Image BrenFal0919 Posted - 1 week ago

$ROIV Be a great time for that share buy back !

User Image renoH4 Posted - 1 week ago

$ROIV.. undervalued, analysts targets above 18 $ This share will rocket. 20 $ should be possible in the next weeks. Have a eye on Arbutus, Roivant has more than 23 % of this gold nugget.

User Image bs010101 Posted - 1 week ago

$ABUS $ROIV Genevant: found on linkedin (i'm unsure how to link to the linkedin post so screenshot)

User Image Joe_Mama Posted - 1 week ago

$ROIV Next target $16.75

User Image jrothman22 Posted - 1 week ago

$ABUS Im bored, so I came up with a hypothetical scenario: $PFE decides it wants to buy Genevant and ABUS. W/the relationship it has with $ROIV its a possibility. Simply a possibility. What price gets it done to allow PFE to buy ABUS & Genevant? I say $10B. You say what?

User Image DG_NY_ Posted - 1 week ago

$ROIV textbook VCP pattern here. Volume supported break through $12 and it’s gone for good.

User Image BrenFal0919 Posted - 1 week ago

$ABUS $ROIV let’s get them Matt !

User Image Capitulation_0 Posted - 1 week ago

$VKTX $PFE needs $VKTX in light of patent suit going on with $MRNA and $ABUS, $ROIV . They know they're next.

User Image PatBull6912 Posted - 1 week ago

$ROIV Filed with the Court yesterday: NOTICE OF SERVICE of 1) Subpoena to Testify at a Deposition in a Civil Action directed to Flagship Pioneering, Inc.; and 2) Subpoena to Produce Documents, Information, or Objects or to Permit Inspection of Premises in a Civil Action directed to Flagship Pioneering, Inc. filed by Genevant Sciences GmbH.(Hoeschen, Nathan) (Entered: 04/04/2024) From Fortune: "Flagship Pioneering is the biotech venture capital firm best-known for funding Moderna, a startup that went from also-ran to household name after it created a highly effective COVID-19 vaccine based on its mRNA technology."

User Image tip2base Posted - 1 week ago

@LM_Johanssen let’s say $ROIV has $7B in cash, 83% of Genevant is worth $10B and they have potential $3B in other drug value currently. Will someone pay $20B for them? I’ll bet that is being discussed in some major pharmaceutical offices.

User Image LM_Johanssen Posted - 1 week ago

$ABUS Does $ROIV holding a large amount of cash make them a more desirable target for acquisition?

User Image AhMrBond Posted - 1 week ago

$ABUS $ROIV $ABUS $ROIV 💥 💥 💥 🚀 🚀 KAMON FOLKS, YES!

User Image BrenFal0919 Posted - 1 week ago

$ABUS $ROIV Make sure u own both!

User Image DocPharm Posted - 1 week ago

$ROIV tick tock…long term cup & handle (years) should be done soon

User Image JxP2000 Posted - 1 week ago

$ACB puts here up and my calls on $roiv are also up. Been a great day so far!

User Image renoH4 Posted - 1 week ago

$ROIV.. But Arbutus should out perform Roivant with more than 100 %

User Image renoH4 Posted - 1 week ago

$ROIV.. guess Moderna pays his billion bill, than Pfizer settles multi billion and the winner is Roivant, second Arbutus and Genevant. Will see minimum 20 $ in the second quarter.

Analyst Ratings
Goldman Sachs Buy Apr 3, 24
HC Wainwright & Co. Buy Apr 3, 24
Deutsche Bank Buy Apr 3, 24
Truist Securities Buy Mar 25, 24
Wolfe Research Outperform Feb 15, 24
HC Wainwright & Co. Buy Feb 14, 24
Piper Sandler Overweight Jan 5, 24
B of A Securities Neutral Jan 2, 24
Deutsche Bank Buy Dec 12, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Venker Eric Chief Operating Offi.. Chief Operating Officer Oct 02 Sell 10.39 1,200,000 12,468,000 595,397 10/04/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Oct 02 Option 3.85 1,200,000 4,620,000 748,424 10/04/23
MANCHESTER KEITH S Director Director Sep 28 Sell 11.55 6,896,144 79,650,463 5,023,787 10/02/23
SVF Investments (UK) Ltd Director Director Sep 28 Sell 12.60 10,000,000 126,000,000 73,031,667 10/02/23
Gold Daniel Allen Director Director Sep 28 Sell 11.55 10,000,000 115,500,000 5,023,787 10/02/23
QVT Financial LP Director Director Sep 28 Sell 11.55 10,000,000 115,500,000 5,023,787 10/02/23
Venker Eric President & COO President & COO Sep 27 Sell 13.02 500,000 6,510,000 595,397 09/29/23
Venker Eric President & COO President & COO Sep 27 Option 3.85 500,000 1,925,000 1,095,397 09/29/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Sep 08 Sell 12.19 106,430 1,297,382 611,813 09/12/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Sep 08 Option 3.85 106,430 409,756 718,243 09/12/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Sep 08 Sell 12.18 99,350 1,210,083 197,950 09/12/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Sep 08 Option 6.48 99,350 643,788 297,300 09/12/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Sep 05 Sell 12 1,724 20,688 197,950 09/07/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Sep 05 Option 6.48 1,724 11,172 199,674 09/07/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Sep 04 Sell 11.89 93,964 1,117,232 611,813 09/06/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Sep 04 Option 3.85 93,964 361,761 617,739 09/06/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Aug 14 Sell 11.89 59,811 711,153 627,918 08/16/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Aug 14 Option 3.85 59,811 230,272 687,729 08/16/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Aug 03 Sell 11.93 44,629 532,424 627,918 08/07/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Aug 03 Option 3.85 44,629 171,822 672,547 08/07/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Aug 01 Sell 12 4,017 48,204 199,328 08/03/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Aug 01 Option 6.48 4,017 26,030 203,009 08/03/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Jul 31 Sell 11.9 195,166 2,322,475 627,918 08/02/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Jul 31 Option 3.85 195,166 751,389 644,315 08/02/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Jul 25 Option 3.85 125,534 483,306 651,540 07/27/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Jul 25 Sell 10.92 125,534 1,370,831 627,918 07/27/23
Venker Eric President & COO President & COO Jul 20 Sell 11.12 374,466 4,164,062 644,215 07/24/23
Venker Eric President & COO President & COO Jul 20 Option 3.85 374,466 1,441,694 677,296 07/24/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Jul 14 Sell 12 635 7,620 82,128 07/18/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Jul 14 Option 6.48 635 4,115 82,228 07/18/23
VIKING GLOBAL INVESTORS LP 10% Owner 10% Owner Jun 22 Sell 9.9 13,000,000 128,700,000 12,884,307 06/26/23
VIKING GLOBAL PERFORMANCE LLC 10% Owner 10% Owner Jun 22 Sell 9.9 13,000,000 128,700,000 12,884,307 06/26/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Jun 09 Sell 9.93 43,893 435,857 198,582 06/13/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Jun 09 Option 5.12 43,893 224,732 242,475 06/13/23
Venker Eric President & COO President & COO Jun 07 Sell 9.88 299,585 2,959,900 660,097 06/09/23
Venker Eric President & COO President & COO Jun 07 Option 3.85 299,585 1,153,402 959,481 06/09/23
Venker Eric President & COO President & COO May 23 Option 3.85 415 1,598 676,183 05/25/23
Venker Eric President & COO President & COO May 23 Sell 9.85 415 4,088 675,768 05/25/23
Venker Eric President & COO President & COO May 09 Sell 9.23 238,724 2,203,423 675,768 05/11/23
Venker Eric President & COO President & COO May 09 Option 3.85 238,724 919,087 914,492 05/11/23
Venker Eric President & COO President & COO May 04 Sell 8.62 150,044 1,293,379 675,768 05/08/23
Venker Eric President & COO President & COO May 04 Option 3.85 150,044 577,669 736,974 05/08/23
Venker Eric President & COO President & COO May 01 Sell 8.43 288,989 2,436,177 675,768 05/03/23
Venker Eric President & COO President & COO May 01 Option 3.85 288,989 1,112,608 794,528 05/03/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer May 01 Sell 8.5 77,736 660,756 200,139 05/03/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer May 01 Option 3.85 77,736 299,284 215,656 05/03/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Apr 26 Sell 8.55 230,788 1,973,237 200,139 04/28/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Apr 26 Option 3.9 230,788 900,073 272,128 04/28/23
Venker Eric President & COO President & COO Apr 26 Sell 8.55 222,243 1,900,178 675,768 04/28/23
Venker Eric President & COO President & COO Apr 26 Option 3.85 222,243 855,636 751,591 04/28/23